The impact ofTegillarca granosaextract haishengsu on HL-60 cell

• Autorzy: Jinshen Wang , Lixia Wei , Yueqin Han , Daogang Qin , Qiaozhi Yang , Xiuli Ju
• Języki publikacji: EN

Abstrakty

EN

Haishengsu (Hss) is a purified protein from Tegillarca granosa that has been used as a traditional Chinese medicine to treat cancer for more than a century. In this study, we observed the impact of Haishengsu (Hss) on the proliferation and differentiation of HL-60 cells in the leukemic cell line by taking tretinoin and AS2O3 as a positive control and making a comparative analysis between the effect of Hss and tretinoin and AS2O3. We found that Hss could significantly inhibit the proliferation of HL-60 cells and caused most of the cells to stay in the G0/G1 phase. Its effect was much stronger than that of tretinoin and AS2O3, and the ability of Hss to induce differentiation was close to tretinoin. Hss functions probably by inhibiting the expression of the Bcl-2 and MPO genes and further promoting the expression of the Bax gene. Hss has a significant effect on both inhibiting the proliferation and inducing the differentiation of HL-60 cells. It is possible that Hss may be a new kind of clinical differentiation inducer.

Słowa kluczowe

EN

Tegillarca granosa; Cell differentiation; Leukemia

• Czasopismo: Open Medicine
• Rocznik: 2014
• Tom: 10
• Numer: 1

Daty

otrzymano

2015-04-06

zaakceptowano

2015-05-25

online

2015-08-03

Twórcy

autor

Jinshen Wang

• Department of Pediatric Hematology,
  Qilu Hospital, Shandong University, 107 West Wenhua Rd, Jinan,
  Shandong 250012, China
• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

autor

Lixia Wei

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

autor

Yueqin Han

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

autor

Daogang Qin

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

autor

Qiaozhi Yang

• Department of Pediatric, Liaocheng People’s Hospital, Liaocheng,
  Shandong, 252000, P.R.China

autor

Xiuli Ju

• Department of Pediatric Hematology,
  Qilu Hospital, Shandong University, 107 West Wenhua Rd, Jinan,
  Shandong 250012, China
• Cryomedicine Laboratory of Qilu Hospital of Shandong University,
  Jinan, Shandong, 250000, P.R.China

Bibliografia

• ---
• [1] Dassonneville L, Wattez N, Baldeyrou B, Mahieu C, Lansiaux A,Banaigs B, et al. Inhibition of topoisomerase II by the marinealkaloid ascididemin and induction of apoptosis in leukemiacells. Biochem Pharmacol 2000, 60: 527-537
• [2] Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate1-beta-D-arabinofuranosylcytosine-induced apoptosis inhuman myeloid leukemia cells through disparate mechanisms.Mol Pharmacol 2003, 63 : 232-242
• [3] Li GY, Liu JZ, Zhang B, Yang M, Chen SG, Hou M, et al. Tegillarcagranosa extract Haishengsu (HSS) suppresses expression ofmdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumorsin mice. Adv Med Sci. 2013;58:112-117
• [4] Xu W, Chang Z, Liu X, Jiang C, Wang C, Xu L. Antitumor effectsof a polypeptide isolated from Tegillarca granosa linnaeusand the related molecular mechanism. Pak J Pharm Sci.2014;27:565-570
• [5] Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, et al. A clinicaland experimental study on all-trans retinoic acid-treated acutepromyelocytic leukemia patients. Blood 1991;78:1413-1419
• [6] Chen SJ, Chen Z, Chen A, Tong JH, Dong S, Wang ZY, et al.Occurrence of distinct PML-RARα fusion gene isoforms inpatients with acute promyelocytic leukemia detected byreverse trascriptase/polymerase chain reaction.Oncogene1992;7:1223-1232
• [7] Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A,Diverio D, et al. Genomic variability and alternative splicinggenerate multiple PML/ RARα transcripts that encode aberrantPML proteins and PML/ RARα isoforms in acute promyelocyticleukemia.EMBO 1992,11:1397-1407
• [8] Wang ZY. Mechanism of action of all-trans retinoic acid andarsenic trioxide in the treatment of acute promyelocyticleukemia. Gan To Kagaku Ryoho, 2002,Suppl 1: 214-218
• [9] Halftermeyer J, Le Bras M, De Thé H． RXR, a key member ofthe oncogenic complex in acute promyelocytic leukemia.MedSci(Paris),2011, 27(11):973-978[WoS]
• [10] Chamarin N, Smith GB, Green A, Andrews MI. Retinoic acidsyndrome. Lancet 1993; 341:1289-1290
• [11] Wang ZY, Chen Z. Acute promyelocytic leukemia: from highlyfatal to highly curable. Blood,2008,111,2505-2515[WoS]
• [12] Tan SM, Hyland RH, Al-Shamkhani A, Douglass WA, Shaw JM,Law SK. Effect of integrin beta 2 subunit trun cations on LFA-1(CD11 a/CD18 ) and Mac-1 (CD11b /CD18) assembly, surfaceexpression, and function. Immuno, 2000; 165: 2574-2581
• [13] Paietta E, Goloubeva O, Neuberg D, Bennett JM, GallagherR, Racevskis J, et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and theassociation of immunophenotypic markers with morphologicand molecular subtypes. Cytometry B Clin Cytom,2004 59:1-9[Crossref]
• [14] Alvarado CS, Austin GE, Borowitz MJ, Shuster JJ, CarrollAJ, Austin ED, et al.Myelopeorxidase gene expression ininfant leukemia:a Pediatric oncology Group Study. LekuLymPhoma,1998,29:145-160
• [15] Serrano J, Román J, Sánchez J, Torres A.Myeloperoxidase geneexpression in acute lymphblastic lekuemia.Br J Haematol,1997; 97:841-843
• [16] Eskes R, Desagher S, Antonsson B, Martinou JC. Bid inducesthe oligomerization and insertion of Bax into the outermitochondrial membrane. Mol Cell Biol, 2000, 20:929-935
• [17] Miramar MD, Costantini P, Ravagnan L, Saraiva LM, HaouziD, Brothers G, et al. NADH oxidase activity of mitochondrialapoptosis-inducing factor. J Biol Chem, 2001 ,276 : 16391-163981

Identyfikatory

DOI

10.1515/med-2015-0048